Stockscreener 앱 받기
22.82
5.66%
-1.37
전일 마감가:
$24.19
열려 있는:
$24.19
하루 거래량:
2.68M
Relative Volume:
1.92
시가총액:
$2.54B
수익:
$-665.00K
순이익/손실:
$-150.11M
주가수익비율:
-15.14
EPS:
-1.5071
순현금흐름:
$-124.53M
1주 성능:
+12.36%
1개월 성능:
+25.59%
6개월 성능:
+63.23%
1년 성능:
+191.07%
1일 변동 폭
$22.56
$24.60
1주일 범위
$19.30
$24.60
52주 변동 폭
$7.48
$24.60
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
명칭
Amylyx Pharmaceuticals Inc
전화
617-682-0917
주소
55 CAMBRIDGE PARKWAY, CAMBRIDGE
Compare AMLX vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
22.82 | 2.17B | -665.00K | -150.11M | -124.53M | -1.5071 |
TAK
Takeda Pharmaceutical Co Adr
|
17.45 | 55.69B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.03 | 43.77B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.36 | 36.19B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
72.66 | 32.25B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
538.84 | 26.29B | 3.17B | 1.29B | 1.01B | 27.09 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-03 | 개시 | Stifel | Buy |
| 2025-07-10 | 재개 | Goldman | Buy |
| 2025-06-24 | 개시 | Guggenheim | Buy |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2025-05-30 | 개시 | TD Cowen | Buy |
| 2025-04-07 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-11-18 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-03-18 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-03-11 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-03 | 개시 | Robert W. Baird | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-07-24 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-03-31 | 개시 | Mizuho | Buy |
| 2023-01-05 | 개시 | BofA Securities | Buy |
| 2022-05-25 | 개시 | Citigroup | Buy |
| 2022-04-01 | 다운그레이드 | Goldman | Buy → Neutral |
모두보기
Amylyx Pharmaceuticals Inc 주식(AMLX)의 최신 뉴스
Amylyx Pharmaceuticals stock hits 52-week high at 19.19 USD - Investing.com
Amylyx Pharmaceuticals stock hits 52-week high at 19.19 USD By Investing.com - Investing.com Canada
Amylyx Pharmaceuticals Inc (AMLX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Institutional Confidence - TradingKey
TradingKey - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Balance Sheet - TradingKey
AMLX|Amylyx Pharmaceuticals Inc|Price:18.410|Chg%:+0.820 - TradingKey
Amylyx Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:AMLX - TradingView
Amylyx Pharmaceuticals Inc (AMLX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Chief Legal Officer & General Counsel Gina Mazzariello Sold A Bunch Of Shares In Amylyx Pharmaceuticals - 富途牛牛
Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $24 - Moomoo
Mizuho raises Amylyx stock price target to $24 ahead of trial data By Investing.com - Investing.com South Africa
Mizuho raises Amylyx stock price target to $24 ahead of trial data - Investing.com Nigeria
Mizuho Raises Price Target on Amylyx Pharmaceuticals to $24 From $21, Keeps Outperform Rating - marketscreener.com
Lobbying Update: $40,000 of AMYLYX PHARMACEUTICALS lobbying was just disclosed - Quiver Quantitative
Trade Alert: Chief Legal Officer & General Counsel Of Amylyx Pharmaceuticals Gina Mazzariello Has Sold Stock - Sahm
Amylyx Pharmaceuticals (AMLX) Holds Steady Near $17.30 Amid Modest Downside – Key Levels in FocusETF Inflow Streak - dars.gov.et
Insider Sell: Gina Mazzariello Sells 30,000 Shares of Amylyx Pha - GuruFocus
Amylyx Pharmaceuticals (AMLX) CLO sells 30,000 shares under 10b5-1 plan - Stock Titan
Amylyx Pharmaceuticals (AMLX) M&A Announcement Summary - Quartr
Amylyx Pharmaceuticals (AMLX) Proxy filing Summary - Quartr
Form 144 Amylyx Pharmaceuticals For: 9 July By Investing.com - Investing.com Nigeria
[144] Amylyx Pharmaceuticals, Inc. SEC Filing - Stock Titan
Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - aol.com
Amylyx Pharmaceuticals (AMLX) Q3 2024 earnings summary - Quartr
Post-Bariatric Hypoglycemia Market to Register Stunning Growth at a 16.4% CAGR Through 2036 Owing to the Emergence of Novel Drug Classes Such as GLP-1 Receptor Antagonists, SGLT1 Inhibitors, CRH Inhibitors, and SSTR5 Agonists | DelveInsight - Yahoo Finance
AMLXAmylyx Pharmaceuticals Inc Latest SEC Filings - Finviz
Analysts Are Bullish on These Healthcare Stocks: Amylyx Pharmaceuticals Inc (AMLX), Guardian Pharmacy Services, Inc. Class A (GRDN) - The Globe and Mail
Companies Like Amylyx Pharmaceuticals (NASDAQ:AMLX) Are In A Position To Invest In Growth - Moomoo
Amylyx Pharmaceuticals (AMLX) Edges Higher Amid Cautious Trading at $17.99Tick Index - DonanımHaber
Amylyx Pharmaceuticals Gains Attention as LUCIDITY Trial Results LoomEarnings Power Value - dars.gov.et
Is Amylyx Pharmaceuticals, Inc. (AMLX) Stock Ready for a Breakout Ahead of Key LUCIDITY Trial Data? - Insider Monkey
Amylyx Pharmaceuticals, Inc.(NasdaqGS: AMLX) dropped from Russell 3000E Index - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS: AMLX) dropped from Russell Microcap Index - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell 3000 Value Benchmark - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell 2500 Value Benchmark - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell 2000 Value Benchmark - marketscreener.com
Enterprise value to EBIT forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gew - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Amylyx advancing ALS treatment in trial after early safety data is positive - ALS News Today
Enterprise value to revenue forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView
Price to sales forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView
Amylyx Pharmaceuticals Inc (AMLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Amylyx Pharmaceuticals Inc 주식 (AMLX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mazzariello Gina | Chief Legal Officer |
Jul 10 '26 |
Sale |
17.61 |
15,000 |
264,122 |
179,090 |
1.65%
8.60%
자본화:
|
볼륨(24시간):